Elanco's Breakthrough Treatment for Deadly Canine Parvovirus Has Saved Thousands of Puppies, Reaffirms Commitment to Increasing the Availability of Canine Parvovirus Monoclonal Antibody for Second Annual National Parvo Awareness Day
Elanco Animal Health (NYSE: ELAN) commemorates the second annual National Parvo Awareness Day, highlighting their breakthrough Canine Parvovirus Monoclonal Antibody (CPMA) treatment. The USDA-conditionally approved CPMA has demonstrated remarkable results with a 93% survival rate for infected puppies, reducing hospital stays by an average of 1.87 days.
Through ParvoTrack, Elanco's pioneering real-time outbreak tracking tool, thousands of cases have been reported nationwide, with Texas, Arizona, Georgia, Florida, Illinois, Indiana, and New York showing the highest outbreak rates. The platform enables pet owners and veterinarians to self-report cases and receive local outbreak alerts.
Elanco has set an ambitious goal to save 1 million puppies from parvovirus by 2030. The company has already saved thousands of puppies in the first year, with success stories including Cookie, Dolly, Patrick, Beatrix, Buster, Luna, and Mono, all of whom made full recoveries after CPMA treatment.
Elanco Animal Health (NYSE: ELAN) celebra il secondo anniversario della Giornata Nazionale di Sensibilizzazione sul Parvovirus, mettendo in luce il loro innovativo trattamento con Anticorpi Monoclonali per il Parvovirus Canino (CPMA). Il CPMA, approvato condizionatamente dall'USDA, ha mostrato risultati straordinari con un tasso di sopravvivenza del 93% nei cuccioli infetti, riducendo la durata media del ricovero di 1,87 giorni.
Attraverso ParvoTrack, lo strumento pionieristico di Elanco per il monitoraggio in tempo reale dei focolai, sono stati segnalati migliaia di casi a livello nazionale, con Texas, Arizona, Georgia, Florida, Illinois, Indiana e New York che mostrano i tassi più alti di diffusione. La piattaforma consente ai proprietari di animali e ai veterinari di segnalare autonomamente i casi e ricevere avvisi sui focolai locali.
Elanco si è posta l'ambizioso obiettivo di salvare 1 milione di cuccioli dal parvovirus entro il 2030. L'azienda ha già salvato migliaia di cuccioli nel primo anno, con storie di successo come quelle di Cookie, Dolly, Patrick, Beatrix, Buster, Luna e Mono, tutti completamente guariti grazie al trattamento con CPMA.
Elanco Animal Health (NYSE: ELAN) conmemora el segundo Día Nacional de Concienciación sobre el Parvovirus, destacando su innovador tratamiento con Anticuerpos Monoclonales para Parvovirus Canino (CPMA). El CPMA, aprobado condicionalmente por el USDA, ha demostrado resultados sobresalientes con una tasa de supervivencia del 93% en cachorros infectados, reduciendo las estancias hospitalarias en un promedio de 1,87 días.
A través de ParvoTrack, la herramienta pionera de Elanco para el seguimiento en tiempo real de brotes, se han reportado miles de casos a nivel nacional, con Texas, Arizona, Georgia, Florida, Illinois, Indiana y Nueva York mostrando las tasas más altas de brotes. La plataforma permite a dueños de mascotas y veterinarios reportar casos y recibir alertas de brotes locales.
Elanco se ha fijado la ambiciosa meta de salvar a 1 millón de cachorros del parvovirus para 2030. La compañía ya ha salvado a miles de cachorros en el primer año, con historias de éxito como las de Cookie, Dolly, Patrick, Beatrix, Buster, Luna y Mono, todos recuperados completamente tras el tratamiento con CPMA.
엘란코 애니멀 헬스(NYSE: ELAN)는 두 번째 연례 전국 파보바이러스 인식의 날을 기념하며 획기적인 개 파보바이러스 단클론 항체(CPMA) 치료법을 소개합니다. USDA 조건부 승인을 받은 CPMA는 감염된 강아지의 93% 생존율을 기록하며 평균 입원 기간을 1.87일 단축하는 뛰어난 효과를 보였습니다.
엘란코의 실시간 발병 추적 도구인 ParvoTrack을 통해 전국적으로 수천 건의 사례가 보고되었으며, 텍사스, 애리조나, 조지아, 플로리다, 일리노이, 인디애나, 뉴욕에서 발병률이 가장 높게 나타났습니다. 이 플랫폼은 반려동물 소유자와 수의사가 직접 사례를 신고하고 지역 발병 알림을 받을 수 있도록 지원합니다.
엘란코는 2030년까지 100만 마리의 강아지를 파보바이러스로부터 구하는 야심찬 목표를 세웠습니다. 회사는 이미 첫 해에 수천 마리의 강아지를 구했으며, 쿠키, 돌리, 패트릭, 비트릭스, 버스터, 루나, 모노 등 CPMA 치료 후 완전히 회복한 성공 사례들이 있습니다.
Elanco Animal Health (NYSE : ELAN) célèbre la deuxième Journée nationale de sensibilisation au parvovirus, mettant en avant leur traitement révolutionnaire par anticorps monoclonaux contre le parvovirus canin (CPMA). Le CPMA, approuvé sous condition par l’USDA, a démontré des résultats remarquables avec un taux de survie de 93 % chez les chiots infectés, réduisant la durée moyenne d’hospitalisation de 1,87 jour.
Grâce à ParvoTrack, l’outil pionnier d’Elanco pour le suivi en temps réel des foyers, des milliers de cas ont été signalés à l’échelle nationale, le Texas, l’Arizona, la Géorgie, la Floride, l’Illinois, l’Indiana et New York affichant les taux de contamination les plus élevés. La plateforme permet aux propriétaires d’animaux et aux vétérinaires de déclarer eux-mêmes les cas et de recevoir des alertes locales sur les foyers.
Elanco s’est fixé un objectif ambitieux : sauver 1 million de chiots du parvovirus d’ici 2030. L’entreprise a déjà sauvé des milliers de chiots lors de la première année, avec des histoires à succès incluant Cookie, Dolly, Patrick, Beatrix, Buster, Luna et Mono, tous guéris complètement après le traitement CPMA.
Elanco Animal Health (NYSE: ELAN) feiert den zweiten jährlichen Nationalen Parvo Awareness Day und hebt dabei ihre bahnbrechende Behandlung mit monoklonalen Antikörpern gegen das canine Parvovirus (CPMA) hervor. Das vom USDA bedingt zugelassene CPMA hat bemerkenswerte Ergebnisse mit einer Überlebensrate von 93% bei infizierten Welpen gezeigt und verkürzt die Krankenhausaufenthalte im Durchschnitt um 1,87 Tage.
Durch ParvoTrack, Elancos innovatives Echtzeit-Ausbruchserfassungstool, wurden landesweit Tausende von Fällen gemeldet, wobei Texas, Arizona, Georgia, Florida, Illinois, Indiana und New York die höchsten Ausbruchsquoten aufweisen. Die Plattform ermöglicht es Tierhaltern und Tierärzten, Fälle selbst zu melden und lokale Ausbruchwarnungen zu erhalten.
Elanco hat sich das ehrgeizige Ziel gesetzt, bis 2030 eine Million Welpen vor dem Parvovirus zu retten. Das Unternehmen hat im ersten Jahr bereits Tausende von Welpen gerettet, mit Erfolgsgeschichten wie Cookie, Dolly, Patrick, Beatrix, Buster, Luna und Mono, die alle nach der CPMA-Behandlung vollständig genesen sind.
- None.
- None.
- National Parvo Awareness Day raises awareness of canine parvovirus (parvo), the often-fatal puppy disease.
- Elanco's Canine Parvovirus Monoclonal Antibody (CPMA) is the first-and-only USDA conditionally approved treatment for parvo.
- Puppies treated with CPMA had a
93% survival rate and returned home an average of 1.87 days sooner.1,2 - Elanco's ParvoTrack, the first-ever national online parvo tracking tool, allows pet owners and veterinarians to self-report outbreaks in real time, further highlighting the need for CPMA across the country and reinforcing Elanco's commitment to increasing the availability of CPMA.
Texas ,Arizona ,Georgia ,Florida ,Illinois ,Indiana andNew York have some of the highest reported cases of canine parvovirus outbreaks according to ParvoTrack.
Experience the full interactive Multichannel News Release here: https://www.multivu.com/elanco/9306451-en-elanco-animal-health-second-annual-national-parvo-awareness-day
"Parvo is a devastating disease that not only impacts our pets, but takes an emotional toll on pet owners, veterinarians and animal health experts," said Dr. Chris George, veterinarian and infectious disease expert at Elanco Animal Health. "Without supportive care, parvo has a
Elanco's mission to save 1 million puppies from parvovirus by 2030
"Making CPMA widely available is crucial in our fight against this devastating virus, including in shelter environments where resources are often strained," said Bobby Modi, Executive Vice President,
Last year, Elanco launched ParvoTrack as the first-ever real-time online parvo tracking tool, empowering pet owners and the veterinary community with innovative intelligence to help notify them of parvo outbreaks in their communities. Visitors to the site can self-report and identify parvo outbreak areas, with a few simple steps, as well as sign up for parvo outbreak alerts in their area. Since launching ParvoTrack last year, thousands of parvo cases have been reported nationwide, with over 7,000 pet owners and veterinarians signing up to receive alerts with outbreaks in their area. ParvoTrack updates in real time and displays data from the past 12 months. Parvo outbreaks have occurred in every state with
"Every clinic and every shelter should have CPMA readily available."
"We've been treating parvo since early 2020 and it can be an absolutely devastating disease that weighs heavily on the staff," said Dr. Meghan Herron, Senior Director of Behavior, Research, and Education at Gigi's, an
Survivor Stories
Here are just a few of the faces that fully recovered from parvovirus after receiving lifesaving CPMA treatment.
Cookie, an 8-week-old pitbull mix puppy from
Dolly, an 8-week-old mixed breed puppy from
Patrick, a 10-week-old terrier mix from
Beatrix, a 3-month-old dalmatian from
Buster, a 12-week-old mixed breed from
Luna, a 10-week-old rat terrier from
Similarly, Mono, a 2-month-old mixed breed who arrived at Paws Chicago after staff was told he required immediate help or face euthanasia; Mono tested positive for parvo and immediately received CPMA. Three days post-treatment, he was up running around.
To learn more about CPMA and report a parvo outbreak or learn which clinics near you carry CPMA, visit ParvoTrack.com.
Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.
©2025 Elanco or its affiliates. PM-US-25-0730
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ sustainability pillars – all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.com.
1 Elanco Animal Health. Market Data on File.
2 Elanco Animal Health. Industry Data on File.
3 Elanco Animal Health. Data on File.
4 Sykes, JE. Canine Parvovirus Infections and Other Viral Enteritides. Canine and Feline Infectious Diseases. 2014:141-151
Investor Contact: Tiffany Kanaga (765) 740-0314 tiffany.kanaga@elancoah.com
Media Contact: Season Solorio (765) 316-0233 season.solorio@elancoah.com


SOURCE Elanco Animal Health